Alnylam’s pioneering science has yielded the critical breakthroughs and innovations that have made RNA interference (RNAi)-based medicines a reality.

We ushered in the first phase of the RNAi RevolutionTM by developing the first five approved RNAi therapeutics. Now, we’re pioneering what’s next, working to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and which impact millions of people around the world.


Silencing genes to disrupt disease

RNA interference (RNAi) is a naturally occurring process already at work inside your body which regulates how genes make new proteins. Proteins play a critical role in almost everything your body does, but sometimes, they can cause or contribute to disease. Our medicines leverage the RNAi process to prevent specific proteins from being made, disrupting disease at its source.

We believe that this revolutionary approach can be used to silence virtually any gene in the genome… meaning that the diseases we’re treating today are just the beginning of what’s possible.


Our robust pipeline of investigational RNAi therapeutics is currently focused on diseases with high unmet medical need, including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases, and neurological diseases. Additionally, we will always follow the science and are continually looking for new disease targets that may benefit from our RNAi technology.


Genetic Medicines


Cardio-Metabolic Diseases


Infectious Diseases


Central Nervous System & Ocular Diseases



While we’re driven by science, we’re motivated by people because for us, this is personal. Whether we're working to develop the first treatment for a disease or a better one, patients are the center of all we do. They are the reason we come to work every day, and their stories inspire us to continue to innovate by pushing the science of RNAi therapeutics forward.

My body started to warn me that something was wrong. That I had a problem… My father passed away 40 years ago; after I received my diagnosis, we believe what he really had was hATTR amyloidosis like me.

-Chen, living with hATTR amyloidosis



HELIOS-B Phase 3 Topline Results
Alnylam announces positive topline results from the Phase 3 clinical trial of vutrisiran
view article ›
Corporate Responsibility at Alnylam
Corporate Responsibility at Alnylam
We’ve published our fourth annual Corporate Responsibility Report
view article ›
Alnylam Publishes 2023 Annual Report
Alnylam Publishes 2023 Annual Report
CEO Yvonne Greenstreet highlights another year of continued RNAi innovation
view article ›
Alnylam Reports Positive KARDIA-2 Topline Study Results
Zilebesiran demonstrated clinically significant blood pressure reductions when added to standard of care antihypertensives
view article ›
This is our 9th consecutive
Alnylam Named #1 Largest Employer in Massachusetts 3 Years in a Row
This is our 9th consecutive year on The Boston Globe Top Places to Work list
view article ›


Accepting Challenges to Improve the Health of Humanity

We believe that our actions as a company can be a force for good in the world both inside our labs and beyond. We aspire to make a positive impact in the world beyond the medicines we make through focusing on patients, science, employees, communities, our planet and corporate governance.


We're Driven to Change the World

We are proud of the award-winning, open, dynamic, and diverse culture we have built. Here, our employees feel included, supported, and heard. We are committed to building a work environment with a shared mission and values, where all employees are enabled to achieve their full potential.


Job Seekers

This is your moment to join us

We're 2,000+ smart, passionate, "change the world" kind of people who believe deeply in the power and potential of our technology and what we're building as a company. If you are looking for a mission, colleagues that inspire, and a company that recognizes and rewards both group and individual contributions, perhaps this is your moment to join us.